Ladenburg starts Alterity at Buy, sees potential for MSA path as 'shortcut'
Ladenburg analyst Aydin Huseynov initiated coverage of Alterity Therapeutics with a Buy rating and $2 price target. ATH434's first indication being investigated is Multiple System Atrophy, or MSA, an orphan disease that shares similar features with Parkinson's disease, or PD, said Huseynov, who views the clinical development path for the MSA indication as "a shortcut to FDA approval." He likes Alterity because of its focus on MSA and what he sees as "a scientifically sound relation between iron chelation and the severity of MSA disease."
Some recent news about ATH
- Forums
- ASX - By Stock
- Life Bio is keeping dumping
Ladenburg starts Alterity at Buy, sees potential for MSA path as...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $18.62M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $3.04K | 865.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
39 | 49079493 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 127051874 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 49079493 | 0.003 |
63 | 91708098 | 0.002 |
29 | 123121099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 127051874 | 19 |
0.005 | 31473632 | 28 |
0.006 | 15253927 | 25 |
0.007 | 55868969 | 31 |
0.008 | 23800417 | 27 |
Last trade - 15.42pm 12/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |